How dominant is Pfizer in ATTR-CM?
Critics point not to clinical differentiation alone but to a range of commercial tactics — misleading 'first and only' claims, patent settlements to 2031, Vyndaqel's discontinuation to protect the 2035 patent, and formulary-level rebate advantages.
Although Pfizer maintains a dominant market share, critics point to a range of commercial tactics, rather than clinical differentiation alone, to explain how it has held on to it. Critics cite promotional claims they say overstate Vyndamax's position, such as describing it as the "first and only approved treatment" after competitors had launched. They also point to patent settlements that delay generic entry to 2031, the discontinuation of Vyndaqel ahead of its 2028 patent expiry, which moved patients to a formulation protected until 2035, and rebate-driven formularies that can favour incumbents with large patient bases.